Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Oral coadministration of β-glucuronidase to increase exposure of extensively glucuronidated drugs that undergo enterohepatic recirculation.

Eichenbaum G, Hsu CP, Subrahmanyam V, Chen J, Scicinski J, Galemmo RA Jr, Tuman RW, Johnson DL.

J Pharm Sci. 2012 Jul;101(7):2545-56. doi: 10.1002/jps.23113. Epub 2012 Mar 30.

PMID:
22473491
2.

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.

Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, Chaikin MA, Donatelli RR, Franks CF, Zeng L, Crysler C, Chen Y, Yurkow EJ, Boczon L, Meegalla SK, Wilson KJ, Wall MJ, Chen J, Ballentine SK, Ott H, Baumann C, Lawrence D, Tomczuk BE, Molloy CJ.

Mol Cancer Ther. 2009 Nov;8(11):3151-61. doi: 10.1158/1535-7163.MCT-09-0255. Epub 2009 Nov 3.

3.

Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.

Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, Zhou Z, Huebert N, Bursell SE, Clermont AC, Grant MB, Shaw LC, Mousa SA, Galemmo RA Jr, Johnson DL, Maryanoff BE, Damiano BP.

J Pharmacol Exp Ther. 2008 Mar;324(3):894-901. Epub 2007 Dec 14.

PMID:
18083913
4.

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.

Arts J, Angibaud P, Mariën A, Floren W, Janssens B, King P, van Dun J, Janssen L, Geerts T, Tuman RW, Johnson DL, Andries L, Jung M, Janicot M, van Emelen K.

Br J Cancer. 2007 Nov 19;97(10):1344-53. Epub 2007 Nov 13.

5.

N-glucuronidation of the platelet-derived growth factor receptor tyrosine kinase inhibitor 6,7-(dimethoxy-2,4-dihydroindeno[1,2-C]pyrazol-3-yl)-(3-fluoro-phenyl)-amine by human UDP-glucuronosyltransferases.

Yan Z, Caldwell GW, Gauthier D, Leo GC, Mei J, Ho CY, Jones WJ, Masucci JA, Tuman RW, Galemmo RA Jr, Johnson DL.

Drug Metab Dispos. 2006 May;34(5):748-55. Epub 2006 Feb 2.

PMID:
16455802
6.

(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.

Ho CY, Ludovici DW, Maharoof US, Mei J, Sechler JL, Tuman RW, Strobel ED, Andraka L, Yen HK, Leo G, Li J, Almond H, Lu H, DeVine A, Tominovich RM, Baker J, Emanuel S, Gruninger RH, Middleton SA, Johnson DL, Galemmo RA Jr.

J Med Chem. 2005 Dec 29;48(26):8163-73.

PMID:
16366598
7.
8.

Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2).

Garrabrant T, Tuman RW, Ludovici D, Tominovich R, Simoneaux RL, Galemmo RA Jr, Johnson DL.

Angiogenesis. 2004;7(2):91-6.

PMID:
15516829
9.

1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.

Ghosh S, Santulli RJ, Kinney WA, Decorte BL, Liu L, Lewis JM, Proost JC, Leo GC, Masucci J, Hageman WE, Thompson AS, Chen I, Kawahama R, Tuman RW, Galemmo RA Jr, Johnson DL, Damiano BP, Maryanoff BE.

Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41.

PMID:
15501072
10.

Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.

De Corte BL, Kinney WA, Liu L, Ghosh S, Brunner L, Hoekstra WJ, Santulli RJ, Tuman RW, Baker J, Burns C, Proost JC, Tounge BA, Damiano BP, Maryanoff BE, Johnson DL, Galemmo RA Jr.

Bioorg Med Chem Lett. 2004 Oct 18;14(20):5227-32.

PMID:
15380233
11.

A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.

Emanuel S, Gruninger RH, Fuentes-Pesquera A, Connolly PJ, Seamon JA, Hazel S, Tominovich R, Hollister B, Napier C, D'Andrea MR, Reuman M, Bignan G, Tuman R, Johnson D, Moffatt D, Batchelor M, Foley A, O'Connell J, Allen R, Perry M, Jolliffe L, Middleton SA.

Mol Pharmacol. 2004 Sep;66(3):635-47.

PMID:
15322256
12.

Synthesis and anti-angiogenic activity of 6-(1,2,4-thiadiazol-5-yl)-3-amino pyridazine derivatives.

Bongartz JP, Stokbroekx R, Van der Aa M, Luyckx M, Willems M, Ceusters M, Meerpoel L, Smets G, Jansen T, Wouters W, Bowden C, Valletta L, Herb M, Tominovich R, Tuman R.

Bioorg Med Chem Lett. 2002 Feb 25;12(4):589-91. Erratum in: Bioorg Med Chem Lett. 2002 Apr 8;12(7):1133-4.

PMID:
11844678
13.

Automatic vessel segmentation and quantification of the rat aortic ring assay of angiogenesis.

Nissanov J, Tuman RW, Gruver LM, Fortunato JM.

Lab Invest. 1995 Nov;73(5):734-9.

PMID:
7474948
14.

A novel series of N-(1-aminoalkylidene)carboximidamides as potential hypoglycemic agents.

Breslin HJ, Kukla MJ, Tuman RW, Rebarchak MC, Bowden CR.

J Med Chem. 1993 May 28;36(11):1597-603.

PMID:
8496927
15.

Effect of linogliride on hormone release from perfused rat pancreas. Fuel dependence and desensitization by tolbutamide.

Ronner P, Cheong E, Khalid P, Tuman RW, Matschinsky FM.

Diabetes. 1991 Jul;40(7):878-84.

PMID:
2060724
16.

Inhibition of peripheral aromatization in the male cynomolgus monkey by a novel nonsteroidal aromatase inhibitor (R 76713).

Tuman RW, Morris DM, Wallace NH, Bowden CR.

J Clin Endocrinol Metab. 1991 Apr;72(4):755-60.

PMID:
2005200
17.

New non-steroidal aromatase inhibitors: focus on R76713.

De Coster R, Wouters W, Bowden CR, Vanden Bossche H, Bruynseels J, Tuman RW, Van Ginckel R, Snoeck E, Van Peer A, Janssen PA.

J Steroid Biochem Mol Biol. 1990 Nov 20;37(3):335-41. Review.

PMID:
2257238
18.

Carbohydrate biguanides as potential hypoglycemic agents.

Reitz AB, Tuman RW, Marchione CS, Jordan AD Jr, Bowden CR, Maryanoff BE.

J Med Chem. 1989 Sep;32(9):2110-6.

PMID:
2769683
19.
20.

Aromatase inhibition by R 76713: experimental and clinical pharmacology.

Wouters W, De Coster R, Tuman RW, Bowden CR, Bruynseels J, Vanderpas H, Van Rooy P, Amery WK, Janssen PA.

J Steroid Biochem. 1989;34(1-6):427-30.

PMID:
2696850
22.
23.

Influence of the oral hypoglycemic agent linogliride (McN-3935) on insulin secretion from isolated rat islets of Langerhans.

Zawalich WS, Rasmussen G, Tuman RW, Tutwiler GF.

Endocrinology. 1987 Mar;120(3):880-5.

PMID:
3542516
24.

Comparison and effects of natural and synthetic glucose tolerance factor in normal and genetically diabetic mice.

Tuman RW, Bilbo JT, Doisy RJ.

Diabetes. 1978 Jan;27(1):49-56. No abstract available.

PMID:
340311
25.

Supplemental Content

Support Center